Axsome Therapeutics Inc
AXSM102.660USD
-0.360-0.35%
交易中 （美東）報價延遲15分鐘
5.05B總市值
虧損本益比TTM
關於 Axsome Therapeutics Inc 公司
Axsome Therapeutics, Inc. 是一家商業階段的生物製藥公司。該公司致力於開發和提供針對中樞神經系統 (CNS) 的療法，這些疾病的治療選擇有限。該公司的兩種商業產品和開發項目是 Auvelity 和 Sunosi。Auvelity（右美沙芬-布丙酮）是一種口服 N-甲基-D-天冬氨酸 (NMDA) 受體拮抗劑，具有多模態活性，用於治療重度抑鬱症 (MDD)。Sunosi (solriamfetol) 是一種口服藥物，用於治療發作性睡病或阻塞性睡眠呼吸暫停患者的過度日間嗜睡 (EDS)。AXS-05 是一種口服、研究性 NMDA 受體拮抗劑，具有多模態活性，正在開發用於治療阿爾茨海默病躁動 (AD 躁動) 和戒菸。 AXS-07 是一種口服、快速吸收、多機制的試驗藥物，正在開發用於治療偏頭痛的急性治療。
公司簡介
公司代碼AXSM
公司名稱Axsome Therapeutics Inc
上市日期Nov 19, 2015
CEODr. Herriot Tabuteau, M.D.
員工數量683
證券類型Ordinary Share
年結日Nov 19
公司地址One World Trade Center, 29Th Floor
城市NEW YORK
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編10007
電話12123323241
網址https://www.axsome.com/
公司代碼AXSM
上市日期Nov 19, 2015
CEODr. Herriot Tabuteau, M.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Independent Director
Independent Director
167.67K
--
Mr. Nick Pizzie, CPA
Mr. Nick Pizzie, CPA
Chief Financial Officer
Chief Financial Officer
42.67K
-1.00%
Mr. Mark E. Saad
Mr. Mark E. Saad
Independent Director
Independent Director
10.30K
--
Dr. Herriot Tabuteau, M.D.
Dr. Herriot Tabuteau, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
7.23K
--
Mr. Mark L. Jacobson
Mr. Mark L. Jacobson
Chief Operating Officer
Chief Operating Officer
5.78K
--
Mr. Hunter Murdock
Mr. Hunter Murdock
General Counsel
General Counsel
--
--
Dr. Susan M. (Sue) Mahony, Ph.D.
Dr. Susan M. (Sue) Mahony, Ph.D.
Independent Director
Independent Director
--
--
Dr. Mark Coleman, M.D.
Dr. Mark Coleman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Ari Maizel
Mr. Ari Maizel
Chief Commercial Officer
Chief Commercial Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Independent Director
Independent Director
167.67K
--
Mr. Nick Pizzie, CPA
Mr. Nick Pizzie, CPA
Chief Financial Officer
Chief Financial Officer
42.67K
-1.00%
Mr. Mark E. Saad
Mr. Mark E. Saad
Independent Director
Independent Director
10.30K
--
Dr. Herriot Tabuteau, M.D.
Dr. Herriot Tabuteau, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
7.23K
--
Mr. Mark L. Jacobson
Mr. Mark L. Jacobson
Chief Operating Officer
Chief Operating Officer
5.78K
--
Mr. Hunter Murdock
Mr. Hunter Murdock
General Counsel
General Counsel
--
--
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2023
FY2023Q4
FY2023Q3
業務USD
名稱
營收
佔比
Auvelitv
96.23M
79.23%
Sunosi
24.13M
19.86%
Sunosi royality revenue
1.10M
0.91%
地區USD
名稱
營收
佔比
United States
119.41M
98.31%
Outside of the United States
2.05M
1.69%
業務
地區
業務USD
名稱
營收
佔比
Auvelitv
96.23M
79.23%
Sunosi
24.13M
19.86%
Sunosi royality revenue
1.10M
0.91%
股東統計
更新時間: 7月12日 週六
更新時間: 7月12日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Antecip Capital, L.L.C.
14.92%
The Vanguard Group, Inc.
7.86%
BlackRock Institutional Trust Company, N.A.
6.03%
RTW Investments L.P.
5.94%
BVF Partners L.P.
3.43%
Other
61.82%
持股股東
持股股東
佔比
Antecip Capital, L.L.C.
14.92%
The Vanguard Group, Inc.
7.86%
BlackRock Institutional Trust Company, N.A.
6.03%
RTW Investments L.P.
5.94%
BVF Partners L.P.
3.43%
Other
61.82%
股東類型
持股股東
佔比
Investment Advisor
33.54%
Investment Advisor/Hedge Fund
22.21%
Corporation
14.92%
Hedge Fund
14.24%
Research Firm
2.73%
Private Equity
1.51%
Individual Investor
1.39%
Pension Fund
1.17%
Sovereign Wealth Fund
0.82%
Other
7.48%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
614
46.10M
93.63%
-4.69M
2025Q1
613
46.35M
94.71%
-3.83M
2024Q4
570
46.09M
94.52%
-5.46M
2024Q3
540
47.31M
97.60%
-6.48M
2024Q2
526
49.58M
103.45%
-2.44M
2024Q1
512
47.53M
101.57%
-4.95M
2023Q4
484
47.45M
101.62%
-3.96M
2023Q3
475
47.05M
100.91%
-2.63M
2023Q2
475
45.53M
98.82%
+628.64K
2023Q1
467
40.73M
95.65%
-3.70M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Antecip Capital, L.L.C.
7.34M
14.92%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
3.87M
7.86%
-26.20K
-0.67%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.97M
6.03%
-40.30K
-1.34%
Mar 31, 2025
RTW Investments L.P.
2.92M
5.94%
-1.13M
-27.86%
Mar 31, 2025
BVF Partners L.P.
1.69M
3.43%
+302.16K
+21.77%
Mar 31, 2025
Macquarie Investment Management
976.26K
1.98%
+12.21K
+1.27%
Mar 31, 2025
Geode Capital Management, L.L.C.
934.85K
1.9%
+22.32K
+2.45%
Mar 31, 2025
Fidelity Management & Research Company LLC
916.73K
1.86%
+275.45K
+42.95%
Mar 31, 2025
State Street Global Advisors (US)
906.02K
1.84%
-41.23K
-4.35%
Mar 31, 2025
Fairmount Funds Management LLC
815.18K
1.66%
-653.81K
-44.51%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
SPDR S&P Pharmaceuticals ETF
3.7%
ALPS Medical Breakthroughs ETF
3.47%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.62%
Tema Neuroscience and Mental Health ETF
2.52%
iShares U.S. Pharmaceuticals ETF
2.17%
Virtus LifeSci Biotech Products ETF
1.89%
First Trust Mid Cap Growth AlphaDEX Fund
0.6%
iShares Health Innovation Active ETF
0.59%
Invesco Nasdaq Biotechnology ETF
0.57%
ProShares Ultra Nasdaq Biotechnology
0.57%
查看更多
SPDR S&P Pharmaceuticals ETF
佔比3.7%
ALPS Medical Breakthroughs ETF
佔比3.47%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比2.62%
Tema Neuroscience and Mental Health ETF
佔比2.52%
iShares U.S. Pharmaceuticals ETF
佔比2.17%
Virtus LifeSci Biotech Products ETF
佔比1.89%
First Trust Mid Cap Growth AlphaDEX Fund
佔比0.6%
iShares Health Innovation Active ETF
佔比0.59%
Invesco Nasdaq Biotechnology ETF
佔比0.57%
ProShares Ultra Nasdaq Biotechnology
佔比0.57%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
